DefiniGEN Licenses CRISPR-Cas9 Gene Editing Technology from Broad Institute to Develop Cell Models for Optimized Metabolic Disease Drug Development

publication date: Nov 15, 2018
 | 
author/source: DefiniGEN

DefiniGENDefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes.

Broad Institute CRISPR-Cas9 technology will be combined with DefiniGEN’s best-in-class induced Pluripotent Stem Cell (iPSC) differentiation platform to generate preclinical cell models which can accelerate Type 2 diabetes, non-alcoholic steatohepatitis (NASH), and orphan liver disease drug discovery programmes.

"Through our license with Broad Institute, we are pleased to be able to enhance our customer’s research programs by offering state-of-the-art CRISPR-Cas9 gene edited disease model cell products and custom services," commented Dr Marcus Yeo CEO of DefiniGEN.

DefiniGEN will produce CRISPR-Cas9 gene edited cells, enabling customers to exploit the power of genome editing, alongside world-leading stem cell production and disease modelling capabilities.


 

Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!

Newsletters from Lab Bulletin

 

Request your free copies HERE

 

 

 

Popular this Month

Top 10 most popular articles this month

 

 

Today's Picks

 


 

Looking for a Supplier?

Search by company or by product

 


Company Name:

Product:


 

 

 

 

Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd.